Physiogenex
Hamster models of MetALD

Physiogenex
THE METABOLIC DISEASES EXPERTS

Effects of incretin-based therapies on alcohol intake in lean hamsters

Golden Syrian hamsters, male, 10-week old, n=18

•group randomization: body weight

Treatment groups (2 hamsters per cage):
- •group 1: vehicle s.c. every 3 days, n=6
- •group 2: semaglutide 0.04mg/kg s.c. every 3 days, n=6
- •group 3: tirzepatide 0.05mg/kg s.c. every 3 days, n=6

- •blood, brain and liver collection
- •plasma lipids
- •liver lipids
- •brain and liver histology

Physiogenex
THE METABOLIC DISEASES EXPERTS

Alcohol intake increases by 250% in lean hamsters with free access to alcohol for 4 weeks









Physiogenex
THE METABOLIC DISEASES EXPERTS

Semaglutide (GLP-1r agonist) and tirzepatide (GLP-1r/GIPr dual agonist) both reduces alcohol intake in lean hamsters with free access to alcohol





Physiogenex
THE METABOLIC DISEASES EXPERTS

Contact us

Interested in this model?

Looking for additional data?

Click below:

https://www.physiogenex.com/contact-physiogenex-team/

Physiogenex
THE METABOLIC DISEASES EXPERTS

Effects of semaglutide and lanifibranor in the obese MASH hamster model with free access to alcohol

chow diet
normal water

high fat/cholesterol diet
10% fructose water
+15% alcohol

> 20-week free choice diet fed hamsters,
> 24-week old, male

body weight / food intake and water intake follow-up

free choice diet with 15% alcohol in fructose-enriched water

5-week treatment period with vehicle/semaglutide/lanifibranor

- randomization procedure: ALT, AST and body weight
- blood and liver collection for biochemistry and histology

Physiogenex
THE METABOLIC DISEASES EXPERTS

Both semaglutide and lanifibranor lower alcohol+fructose intake in obese MASH hamsters













Physiogenex
THE METABOLIC DISEASES EXPERTS

While semaglutide is neutral, lanifibranor lowers liver steatosis and reduces histopathological scores in obese MASH hamsters with free access to alcohol















Physiogenex
THE METABOLIC DISEASES EXPERTS

Contact us

Interested in this model?

Looking for additional data?

Click below:

https://www.physiogenex.com/contact-physiogenex-team/

Physiogenex
THE METABOLIC DISEASES EXPERTS

MERCI POUR VOTRE ATTENTION

Physiogenex

THE METABOLIC DISEASES EXPERTS